Jump to content

New Oxymetazoline Cream 1% (Rhofade)


Recommended Posts

  • Root Admin

Allergan announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for oxymetazoline HCl cream 1%  (Rhofade) for the treatment of persistent facial erythema associated with rosacea in adults. MPR

Should be released sometime in 2017. 

The name Rhofade is mentioned in this article

Allergan Plc (AGN) Brenton L. Saunders on Q2 2016 Results – Earnings Call Transcript

A document prepared for Allergan’s November 4, 2015 R&D Day presentation is available to download which is primarily about this new Oxymetazoline 1% Cream which may be released next year. David Pascoe has some insightful comments about this document worth reading. 

FDA has approved Rhofade.

Link to comment
Share on other sites

  • 4 weeks later...

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • Create New...

Important Information

Terms of Use